Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standard-dose versus low-dose prolonged-infusion gemcitabine in advanced pancreatic cancer
PACTR201901862142418Phase 2Completed
- Sponsor
- South Egypt Cancer Institute
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine in pancreatic cancer (PC), sponsored by South Egypt Cancer Institute. Primary endpoints: Progression-free survival and Safety. Started Feb 2016; status: completed.
02
Drugs
gemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on PACTR201901862142418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201901862142418.